Frontlight ResearchEarly access
Taking peoplePhase 3
Efficacy and safety of adjunctive IgM-enriched immunoglobulin therapy with a personalized dose based on serum IgM-titers vs. standard dose in patients with septic shock. A multicenter, interventional, randomized, single-blinded, two arms, adaptive study design.
Key facts
- Who runs it
- Azienda Ospedaliero Universitaria Di Modena
- Where
- Italy9 sites in 1 countryChoose a country to see its sites
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 356 people, planned
- Started
- 11 Nov 2024
- Planned end
- 19 Feb 2025
- Type of study
- Interventional
- Record updated
- 4 April 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Age > 18 years; 2. Septic shock occurrence < 24 hours; septic shock is identified according to Sepsis-3 definition by a vasopressor requirement to maintain a mean arterial pressure of 65 mm Hg or greater and serum lactate level greater than 2 mmol/L (>18 mg/dL) in the absence of hypovolemia in patients with sepsis2. Sepsis is defined as a life threatening organ dysfunction identified as an acute change in total SOFA score ≥2 points consequent to the infection; 3. IgM-titers< 60mg/dl (or < 20% of the lower threshold value of local laboratory) within 24 hours from shock occurrence
Who cannot take part
- Shock of uncertain diagnosis; 2. Hypersensitivity to IgM Preparation in use or its excipients; 3. Patients receiving intravenous immunoglobulins (e.g. IgG or IgM enriched preparations) for > 6 hours before enrolment; 4. Selective absolute IgA deficiency with antibodies to IgA; 5. Pregnancy or breastfeeding or positive pregnancy test. In childbearing age women, before inclusion, a pregnancy test will be performed if not available; 6. Clinical decision to withhold life-sustaining treatment or “too sick to benefit”; 7. Neutrophil count <1.000/mm3; 8. Presence of other severe diseases impairing life expectancy (e.g. patients are not expected to survive 28 days given their pre-existing medical condition); 9. Patients with a known, chronic kidney dysfunction needing dialysis (creatinine ≥ 3.4 mg/dl or creatinine clearance ≤ 30 ml/min/1.73m2); 10. Body Mass Index (BMI) >40; 11. Participation in other clinical trials on adjunctive therapies for sepsis (during past 3 months); 12. Lack or withdrawal of informed consent
This trial is currently available in Italy.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The primary objective is to verify the hypothesis that an adjunctive therapy with IgM-enriched immunoglobulin with a personalized dose based on serum IgM-titers is more effective in reducing any-cause mortality in patients with septic shock compared to a flat dose therapy. Mortality will be measured at 28 days.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 4 April 2025